What is Mustbio?
Mustbio is a specialized biotechnology enterprise dedicated to the advancement of next-generation immuno-oncology solutions. The company distinguishes itself through the development of innovative multi-specific and multi-antibody platform technologies designed to enhance the immune system's tumor-fighting capabilities. By focusing on tumor-selective immuno-cytokines, Mustbio aims to improve both the safety profile and the therapeutic impact of cancer treatments. Its research-driven approach is centered on overcoming the efficacy barriers associated with traditional oncology modalities, positioning the firm as a significant player in the competitive landscape of targeted cancer therapeutics.
How much funding has Mustbio raised?
Mustbio has raised a total of $23.5M across 1 funding round:
Series C
$23.5M
Series C (2026): $23.5M with participation from Premier Partners, Korea Development Bank, Ahn-Gook Pharmaceutical, SHINHAN CAPITAL, Korea Investment Partners, Partners Investment, and WONIK Investment Partners
Key Investors in Mustbio
Premier Partners
Premier Partners is a fund management company focusing on small and mid-cap markets in Korea, established in 2005.
Korea Development Bank
Korea Development Bank is a state-owned policy bank that finances major industrial projects to expedite national economic development.
Ahn-Gook Pharmaceutical
Ahn-Gook Pharmaceutical is a Korean-based pharmaceutical company providing a wide range of ethical and OTC drugs across multiple therapeutic areas.
What's next for Mustbio?
With the successful closure of this major enterprise-level funding, Mustbio is expected to prioritize the expansion of its clinical trial programs and the scaling of its research infrastructure. The strategic focus will likely shift toward validating its lead candidates in human trials, while simultaneously refining its antibody-based platform to address a broader spectrum of tumor types. Given the involvement of institutional and strategic partners, the company is also well-positioned to explore potential co-development opportunities or licensing agreements that could further validate its technology on a global scale. The path forward involves rigorous data generation to support regulatory milestones and long-term commercial viability in the high-stakes oncology market.
See full Mustbio company page
